160/4.5 mcg BDF single inhaler therapy vs current best practice: Withdrawals due to adverse events
160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
160/4.5 mcg BDF single inhaler therapy vs current best practice Discontinuation due to adverse events · adults with asthma that is not controlled on ICS 160/4.5 mcg BDF single inhaler therapy probably leads to higher discontinuation due to adverse events compared with current best practice (moderate certainty). Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice… (2013) · Cochrane Headline outcomes only | OR 2.85 [1.89, 4.3] | 7 studies · 8411 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid… 2013 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.